Risk of bladder cancer in patients with diabetes: A retrospective cohort study

BMJ Open

Volumn 5, Issue 6, 2015, Pages

  Goossens, Maria E ^a   Zeegers, Maurice P ^b   Bazelier, Marloes T ^c   De Bruin, Marie L ^c   Buntinx, Frank ^a,b   De Vries, Frank ^b,c,d,e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; BODY MASS; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SEX; SMOKING; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; COMPLICATION; EPIDEMIOLOGY; MORTALITY; PROGNOSIS; RISK FACTOR; UNITED KINGDOM; URINARY BLADDER NEOPLASMS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED KINGDOM; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84930941981     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-007470     Document Type: Article

References (40)

1. International Diabetes Federation. IDF diabetes atlas. 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
3. Ngwana G, Aerts M, Truyers C, et al. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting. Diabetes Res Clin Pract 2012;97:331-6.
4. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. http://globocan.iarc.fr
5. Goossens ME, Buntinx F, Zeegers MP. Aetiology, demographics and risk factors for bladder cancer. In: The Oxford textbook of surgery. Oxford University Press (OUP). 2015, in press.
6. Larsson SC, Orsini N, Brismar K, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-23.
7. Zhu Z, Zhang X, Shen Z, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS ONE 2013;8:e56662.
8. Xu X, Wu J, Mao Y, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS ONE 2013;8: e58079.
9. Starup-Linde J, Karlstad O, Eriksen SA, et al. CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants-a systematic review and a meta-analysis. Curr Drug Saf 2013;8:296-332.
10. Shu X, Ji J, Li X, et al. Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med 2010;27:791-7.
11. Zendehdel K, Nyren O, Ostenson CG, et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003;95:1797-800.
12. Swerdlow AJ, Laing SP, Qiao Z, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005;92:2070-5.
13. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
14. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
15. La Vecchia C, Negri E, Franceschi S, et al. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994;70:950-3.
16. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-5.
17. Ng Y, Husain I, Waterfall N. Diabetes mellitus and bladder cancer-an epidemiological relationship? Pathol Oncol Res 2003;9:30-1.
18. Verlato G, Drane JW, Aldrich TE. Statistical methods for surveillance of diabetes events. Diabetes Nutr Metab 2003;16:198-200.
19. Larsson SC, Andersson SO, Johansson JE, et al. Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer 2008;44:2655-60.
20. Ogunleye AA, Ogston SA, Morris AD, et al. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 2009;101:1199-201.
21. Attner B, Landin-Olsson M, Lithman T, et al. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control 2012;23:769-77.
22. Hemminki K, Li X, Sundquist J, et al. Risk of cancer following hospitalization for type 2 diabetes. Oncologist 2010;15:548-55.
23. Atchison EA, Gridley G, Carreon JD, et al. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011;128:635-43.
24. Colmers IN, Majumdar SR, Yasui Y, et al. Detection bias and overestimation of bladder cancer risk in type 2 diabetes: a matched cohort study. Diabetes Care 2013;36:3070-5.
25. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012;55:948-58.
26. Johnson JA, Bowker SL, Richardson K, et al. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011;54:2263-71.
27. Kellen E, Zeegers MP, Dirx M, et al. Occurrence of both bladder and prostate cancer in five cancer registries in Belgium, The Netherlands and the United Kingdom. Eur J Cancer 2007;43:1694-700.
28. Kellen E, Zeegers MP, Joniau S, et al. Examining the co-occurrence of bladder and prostate cancer: a worthwhile investigation? Future Oncol 2007;3:515-19.
29. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54:25-31.
30. Diabetes in the UK. Key statistics on diabetes, 2012.
31. Hollowell J. The general practice research database: quality of morbidity data. Popul Trends 1997:36-40.
32. National Service Framework for Diabetes. Department of Health. 2001.
33. Type 1 diabetes-Guidance and guidelines-NICE. 2004. http://wwwniceorguk/guidance/cg15
34. Type 2 diabetes-Guidance and guidelines-NICE. 2009. http://wwwniceorguk/guidance/cg87
35. Peeters PJ, Bazelier MT, Vestergaard P, et al. Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 2013;8:357-63.
36. Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184:E675-83.
37. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013;30:1026-32.
38. de Vries F, Zeegers MP, Knapen LM, et al. Thiazolodinediones and cancer: duplicate publication bias? Oncologist 2013;18:1147.
39. de Vries F, Goossens ME, Zeegers MP. Pioglitazone and bladder cancer: two studies, same database, two answers. Br J Clin Pharmacol 2013;76:484-5.
40. Bazelier MT, de Vries F, Vestergaard P, et al. Use of thiazolidinediones and risk of bladder cancer: disease or drugs? Curr Drug Saf 2013;8:364-70.